The evidence for the efficiency and safety of dapoxetine in treating premature ejaculation

Akhvlediani N.D., Matyukhov I.P.

Urologiia (Moscow, Russia : 1999)

№ 5, С. 106-110

Опубликовано: ## 2017

Тип ресурса: Статья; Обзор

DOI:10.18565/urology.2017.5.106-110

Аннотация:

The aim of the study is to assess the evidence on the efficacy and safety of dapoxetine in premature ejaculation (PE). The analysis includes results of randomized placebo-controlled trials, integrative reviews and one meta-analysis on the clinical efficacy and safety of dapoxetine. All studies have shown higher efficacy of dapoxetine in patients with PE compared with placebo. Its administration at a dosage of 30 and 60 mg results in an increase in the coitus duration up to approximately 3 and 3.5 minutes, respectively. The safety profile of dapoxetine allows using it in clinical practice. Dapoxetine is a novel and effective PE drug on the Russian market.

Рубрики Mesh:

Бензиламины - вредные воздействия

Бензиламины - терапевтическое применение

Человек

Мужской

Нафталины - вредные воздействия

Нафталины - терапевтическое применение

Преждевременная эякуляция

Преждевременная эякуляция - лекарственная терапия

Преждевременная эякуляция - патология

Преждевременная эякуляция - патофизиология

Журнальная статья

Обзор

Язык текста: Русский

ISSN: 1728-2985

Akhvlediani N.D.

Matyukhov I.P.

I.M. Sechenov First MSMU of Minzdrav of Russia Moscow, Russia.

The evidence for the efficiency and safety of dapoxetine in treating premature ejaculation

Текст визуальный электронный

Urologiia (Moscow, Russia : 1999)

№ 5 С. 106-110

2017

dapoxetine

efficacy

premature ejaculation

primaxetin

safety

Статья

Обзор

Benzylamines adverse effects D02.092.200 D02.455.426.559.389.140.210

Benzylamines therapeutic use D02.092.200 D02.455.426.559.389.140.210

Бензиламины вредные воздействия D02.092.200 D02.455.426.559.389.140.210

Бензиламины терапевтическое применение D02.092.200 D02.455.426.559.389.140.210

Humans B01.050.150.900.649.313.988.400.112.400.400

Человек B01.050.150.900.649.313.988.400.112.400.400

Male

Мужской

Naphthalenes adverse effects D02.455.426.559.847.638 D04.615.638

Naphthalenes therapeutic use D02.455.426.559.847.638 D04.615.638

Нафталины вредные воздействия D02.455.426.559.847.638 D04.615.638

Нафталины терапевтическое применение D02.455.426.559.847.638 D04.615.638

Premature Ejaculation C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Premature Ejaculation drug therapy C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Premature Ejaculation pathology C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Premature Ejaculation physiopathology C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Преждевременная эякуляция C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Преждевременная эякуляция лекарственная терапия C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Преждевременная эякуляция патология C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Преждевременная эякуляция патофизиология C12.100.500.530 C12.100.875.743 C12.200.294.530 F03.835.700

Journal Article V02.600

Журнальная статья V02.600

Review V02.600.500 V02.912

Обзор V02.600.500 V02.912

dapoxetine

The aim of the study is to assess the evidence on the efficacy and safety of dapoxetine in premature ejaculation (PE). The analysis includes results of randomized placebo-controlled trials, integrative reviews and one meta-analysis on the clinical efficacy and safety of dapoxetine. All studies have shown higher efficacy of dapoxetine in patients with PE compared with placebo. Its administration at a dosage of 30 and 60 mg results in an increase in the coitus duration up to approximately 3 and 3.5 minutes, respectively. The safety profile of dapoxetine allows using it in clinical practice. Dapoxetine is a novel and effective PE drug on the Russian market.